<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:hpo ids='HP_0006785'>Limb girdle muscular dystrophy</z:hpo>, a <z:hpo ids='HP_0011010'>chronic</z:hpo> progressive muscular <z:e sem="disease" ids="C0151514,C0333641" disease_type="Pathologic Function;Disease or Syndrome" abbrv="">atrophic disease</z:e>, leads to high sensitivity to depolarizing and non-depolarizing neuromuscular blocking agents </plain></SENT>
<SENT sid="1" pm="."><plain>We report the successful use of the sugammadex in a patient with <z:hpo ids='HP_0006785'>limb girdle muscular dystrophy</z:hpo> (dysferlinopathy, Miyoshi distal <z:hpo ids='HP_0003198'>myopathy</z:hpo>) to reverse <z:chebi fb="0" ids="8884">rocuronium</z:chebi>-induced <z:e sem="disease" ids="C0700323,C0235062" disease_type="Disease or Syndrome;Therapeutic or Preventive Procedure" abbrv="">neuromuscular block</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>After neuromuscular recovery to a train-of-four ratio = 43%, we administered 3.2 mg x kg(-1) of sugammadex (200 mg) intravenously, reversing <z:e sem="disease" ids="C0700323,C0234119" disease_type="Disease or Syndrome" abbrv="">neuromuscular blockade</z:e> to a train-of-four ratio = 95% within 3 min </plain></SENT>
<SENT sid="3" pm="."><plain>Sugammadex can be used to reverse <z:chebi fb="0" ids="8884">rocuronium</z:chebi>-induced <z:e sem="disease" ids="C0700323,C0234119" disease_type="Disease or Syndrome" abbrv="">neuromuscular blockade</z:e> in patients with <z:hpo ids='HP_0006785'>limb girdle muscular dystrophy</z:hpo> </plain></SENT>
</text></document>